Rouan Sarah Kathryn 4
4 · Viking Therapeutics, Inc. · Filed Oct 25, 2024
Insider Transaction Report
Form 4
Rouan Sarah Kathryn
Director
Transactions
- Sale
Common Stock, par value $0.00001 per share
2024-10-25$80.89/sh−11,000$889,790→ 0 total - Exercise/Conversion
Common Stock, par value $0.00001 per share
2024-10-25$4.88/sh+11,000$53,680→ 11,000 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-10-25−11,000→ 11,000 totalExercise: $4.88From: 2023-01-03Exp: 2032-01-03→ Common Stock (11,000 underlying)
Footnotes (1)
- [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2024 by the Reporting Person.